Exelixis, Inc. Aktie News

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemot...

Exelixis and Summit Therapeutics could have significant catalysts this year. Both have drug candidates that could drive strong financial results for a while.

Exelixis offers strong growth potential, trading at 14x 2026E EPS, below sector median, with robust oncology franchises and disciplined R&D spending. Cabozantinib remains the near-term growth driver, while zanzalintinib is positioned as the next major oncology franchise, targeting $5B in annual revenue by 2033. EXEL delivered 2025 revenue of $2.32B (+7% YoY), with net product revenue up 17% and...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is avail...

Exelixis offers exceptional medium-term growth, driven by Cabometyx's market leadership and a robust pipeline, yet remains undervalued versus peers. EXEL maintains high profitability and growth without debt, aggressively repurchasing shares and tightly controlling costs to sustain margins. Management is diversifying revenue with new drugs, notably zanzalintinib, while proactively addressing sin...

Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, ...

Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.